Lyell Immunopharma Inc (LYEL)
0.6129
0.00 (0.00%)
USD |
NASDAQ |
Dec 24, 16:00
Lyell Immunopharma Enterprise Value: -269.41M for Dec. 24, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Chimerix Inc | 164.16M |
| NovaBay Pharmaceuticals Inc | 1.919M |
| Palatin Technologies Inc | 16.97M |
| iBio Inc | 11.99M |
| Theriva Biologics Inc | -11.35M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.58M |
| Revenue (Quarterly) | 0.034M |
| Total Expenses (Quarterly) | 50.54M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -131.1K% |
| Earnings Yield | -128.9% |
| Normalized Earnings Yield | -120.55 |